Company intelligence / Profile preview

Flightpath Biosciences

Detroit, Michigan, United Statesflightpath.bio ↗

Ownership: Private
Development stage: Phase 1

Overview

Flightpath's lead drug candidate FP-100 (Hygromycin) has entered Phase 1 clinical trials for Lyme disease as of May 2024. The company has demonstrated selectivity in vitro and efficacy in vivo versus standard-of-care broad spectrum antibiotic therapies.

Therapeutic areas: OtherWomen's HealthOncologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

FP530

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

ADA Forsyth InstituteNortheastern University

Beyond the preview

Go deeper on Flightpath Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flightpath Biosciences.

Explore the full profile